Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 21 citing articles:

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Jian Sheng Loh, Wen Qi Mak, Li Tan, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 231
Insulin resistance as the molecular link between diabetes and Alzheimer's disease
Mona Mohamed Ibrahim Abdalla
World Journal of Diabetes (2024) Vol. 15, Iss. 7, pp. 1430-1447
Open Access | Times Cited: 8
Are glucagon-like peptide-1 receptor agonists anti-consummatory drugs?
Rodrigo B. Mansur, Joshua D. Di Vincenzo, Sebastian Badulescu, et al.
CNS Spectrums (2025), pp. 1-6
Closed Access | Times Cited: 1
Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence
Lívia Cristina Ribeiro Teixeira, Marcelo R. Luizon, Karina Braga Gomes
Receptors (2025) Vol. 4, Iss. 1, pp. 2-2
Open Access | Times Cited: 1
An analysis on the role of glucagon-like peptide-1 receptor agonists in cognitive and mental health disorders
Riccardo De Giorgi, Ana Ghenciulescu, Oliwia Dziwisz, et al.
Nature Mental Health (2025)
Open Access | Times Cited: 1
Comparative efficacy and safety of antidiabetic agents in Alzheimer's disease: A network meta-analysis of randomized controlled trials
Zixin Cai, Jiaxin Zhong, Guanghui Zhu, et al.
The Journal of Prevention of Alzheimer s Disease (2025), pp. 100111-100111
Open Access | Times Cited: 1
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice
Leticia Forny Germano, Jacqueline A. Koehler, Laurie L. Baggio, et al.
Molecular Metabolism (2024) Vol. 89, pp. 102019-102019
Open Access | Times Cited: 6
Comparative outcomes of systemic diseases in people with type 2 diabetes, or obesity alone treated with and without GLP-1 receptor agonists: a retrospective cohort study from the Global Collaborative Network
Mahmoud Nassar, Omar Nassar, Hazem Abosheaishaa, et al.
Journal of Endocrinological Investigation (2024)
Closed Access | Times Cited: 6
The GLP-1 receptor agonist exenatide improves recovery from spinal cord injury by inducing macrophage polarization toward the M2 phenotype
Toshihiro Noguchi, Hiroyuki Katoh, Satoshi Nomura, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 4
Type 2 Diabetes and Cognitive Decline: A Neurovascular Perspective
Arbind Kumar Choudhary
Chronicle of Diabetes Research and Practice (2025) Vol. 4, Iss. 1, pp. 31-41
Closed Access
Role of mitogen-activated protein kinase inhibitors in Alzheimer's disease: Rouge of brain kinases
Suad Hamdan Almasoudi, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Brain Research Bulletin (2025) Vol. 224, pp. 111296-111296
Open Access
Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
Lalitha Sundararaman, Divakara Gouda, Anil Kumar, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 6, pp. 1978-1978
Open Access
Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Riccardo De Giorgi, Ana Ghenciulescu, Courtney Yotter, et al.
Journal of Neurology Neurosurgery & Psychiatry (2025), pp. jnnp-335593
Closed Access
Knowledge domains and emerging trends of Genome-wide association studies in Alzheimer’s disease: A bibliometric analysis and visualization study from 2002 to 2022
Fanjing Kong, Tianyu Wu, Jingyi Dai, et al.
PLoS ONE (2024) Vol. 19, Iss. 1, pp. e0295008-e0295008
Open Access | Times Cited: 2
Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon
Naif H. Ali, Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, et al.
Cellular and Molecular Neurobiology (2024) Vol. 44, Iss. 1
Open Access | Times Cited: 1
To the Brain and Beyond: Neurological Implications of Glucagon-Like Peptide-1 Receptor Agonists
Lindsay R. Hunter Guevara, William B. Beam, Jeffrey J. Pasternak
Journal of Neurosurgical Anesthesiology (2024) Vol. 36, Iss. 4, pp. 278-282
Closed Access | Times Cited: 1
Pathology and Treatments of Alzheimer’s Disease Based on Considering Changes in Brain Energy Metabolism Due to Type 2 Diabetes
Hidekatsu Yanai, Hiroki Adachi, Mariko Hakoshima, et al.
Molecules (2024) Vol. 29, Iss. 24, pp. 5936-5936
Open Access | Times Cited: 1
Impact of GLP-1 Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series
Catherine A Johnson, Jesse Terrell, Lauren S. Blieden, et al.
(2024)
Closed Access
Glucose-Lowering Agents Developed in the Last Two Decades and Their Perioperative Implications
Basavana Goudra, Geno J. Merli, Michael Green
Pharmaceuticals (2024) Vol. 18, Iss. 1, pp. 4-4
Open Access
Banxia Xiexin Decoction Alleviated Cerebral Glucose Metabolism Disorder by Regulating Intestinal Microbiota in APP/PS1 Mice
Chenyan Gao, Gaofeng Qin, Mingcui Zheng, et al.
Chinese Journal of Integrative Medicine (2023) Vol. 30, Iss. 8, pp. 701-712
Closed Access | Times Cited: 1
Page 1

Scroll to top